Provided by Tiger Trade Technology Pte. Ltd.

Pyxis Oncology, Inc.

3.33
-0.0800-2.35%
Post-market: 3.330.00000.00%19:54 EDT
Volume:564.35K
Turnover:1.89M
Market Cap:277.75M
PE:-2.37
High:3.44
Open:3.38
Low:3.33
Close:3.41
52wk High:5.55
52wk Low:1.03
Shares:83.41M
Float Shares:49.56M
Volume Ratio:0.82
T/O Rate:1.14%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-1.4029
EPS(LYR):-1.2813
ROE:-179.10%
ROA:-62.95%
PB:24.28
PE(LYR):-2.60

Loading ...

Pyxis Oncology: MICVO’s Emerging Clinical Profile and Strong Physician Receptivity Support Buy Rating and Unchanged $6 Price Target

TIPRANKS
·
Sep 17

Pyxis Oncology price target raised to $8 from $7 at H.C. Wainwright

TIPRANKS
·
Sep 10

Analyst Maintains Buy Rating on PYXS and Reiterates $6 Price Target on Promising MICVO Data

TIPRANKS
·
Sep 10

Pyxis Oncology is Maintained at Overweight by Wells Fargo

Dow Jones
·
Sep 09

Analysts’ Opinions Are Mixed on These Healthcare Stocks: Pyxis Oncology (PYXS) and Opus Genetics (IRD)

TIPRANKS
·
Sep 09

Pyxis Oncology price target raised to $19 from $12 at Wells Fargo

TIPRANKS
·
Sep 09

Wedbush Lifts Price Target on Pyxis Oncology to $8 From $6, Keeps Outperform Rating

MT Newswires Live
·
Sep 09

Pyxis Oncology Reports Promising MICVO Phase 1 Results

TIPRANKS
·
Sep 09

Pyxis Oncology Releases MICVO Clinical Update Presentation

Reuters
·
Sep 09

Pyxis Oncology Announces Positive Updated Data from Phase 1 Monotherapy Study of Micvotabart Pelidotin (Micvo) in Second-Line and Beyond Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (2L+ R/M Hnscc)

THOMSON REUTERS
·
Sep 09

Pyxis Oncology - Median Progression-Free Survival 6.2 Months, 12-Month Overall Survival Probability 79%

THOMSON REUTERS
·
Sep 09

Pyxis Oncology - Micvo Demonstrates 36% Confirmed Objective Response Rate and 94% Disease Control Rate in Phase 1

THOMSON REUTERS
·
Sep 09

Pyxis Oncology - no New Safety Signals Observed; Dose Capping Reduced Adverse Events in High Body Weight Patients

THOMSON REUTERS
·
Sep 09

Pyxis Oncology to Webcast Updated Phase 1 MICVO Monotherapy Data in Recurrent/metastatic Head and Neck Cancer

Reuters
·
Sep 09

Press Release: Pyxis Oncology Appoints Thomas Civik Chief Executive Officer and Chairman of the Board

Dow Jones
·
Sep 08

Pyxis Oncology Interim CEO Tom Civik Joins Fireside Chat at Wells Fargo Annual Healthcare Conference

Reuters
·
Sep 01

Pyxis Oncology to Participate in Upcoming Investor Conferences

GlobeNewswire
·
Sep 01

Pyxis Oncology files to sell 39.2M shares of common stock for holders

TIPRANKS
·
Aug 21

Pyxis Oncology Price Target Maintained with a $7.00/Share by HC Wainwright & Co.

Dow Jones
·
Aug 18

Buy Rating Reiterated on Pyxis Ahead of Pivotal MICVO Phase 1 Readout; $7 Price Target Maintained

TIPRANKS
·
Aug 18